Total Jobs Filled:
Our relationship with NPS Pharmaceuticals began in 2007 when the company was pursuing an indication in osteoporosis. While they were initially unsuccessful, their unfortunate situation caused them to name a new CEO. The Hennessy Group already had a relationship with this CEO. In fact, we placed him on his first public company board in 2009.
2010 – Head of Pre-Clinical R&D
2010 – VP Clinical Development
2011 – Head of Medical Affairs
2011 – Chief Commercial Officer
2012 – VP Global Regulatory Affairs
When we began partnering with NPS, they had no approved products. By leveraging our network in orphan products, we were able to introduce several senior level executives who were instrumental in getting two products approved, and ultimately to market.
In 2015, Shire PLC acquired NPS pharmaceuticals for $5.2 billion.